JAZZ:NSD-Jazz Pharmaceuticals PLC (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 122.48

Change

+1.64 (+1.36)%

Market Cap

USD 7.29B

Volume

0.57M

Analyst Target

USD 164.82
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+11.73 (+2.74%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+14.61 (+2.15%)

USD 78.92B
ARGX argenx NV ADR

+12.35 (+1.93%)

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

+9.00 (+3.38%)

USD 30.22B
MRNA Moderna Inc

+3.89 (+10.10%)

USD 18.29B
RPRX Royalty Pharma Plc

+0.54 (+1.80%)

USD 18.12B
UTHR United Therapeutics Corporatio..

+0.61 (+0.16%)

USD 15.91B
SMMT Summit Therapeutics PLC

+1.13 (+4.80%)

USD 13.43B
INCY Incyte Corporation

+0.12 (+0.17%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.17 (+0.27%)

USD 12.74B

ETFs Containing JAZZ

CBDP:LSE 25.02 % 0.00 %

N/A

N/A
CBDX:SW 22.54 % 0.00 %

N/A

N/A
FLWR:SW 17.64 % 0.00 %

N/A

N/A
YOLO AdvisorShares Pure Cannab.. 4.03 % 0.00 %

-0.04 (0%)

USD 0.03B
ETLI:XETRA L&G Pharma Breakthrough U.. 3.33 % 0.00 %

+0.05 (+0%)

USD 0.02B
FHH:CA First Trust AlphaDEX US H.. 2.66 % 0.77 %

+0.03 (+0%)

CAD 0.01B
JHSC John Hancock Multifactor .. 0.00 % 0.50 %

+0.10 (+0%)

USD 0.52B
HMMJ-U:CA Global X Marijuana Life S.. 0.00 % 0.00 %

-0.09 (0%)

CAD 0.09B
HMMJ:CA Global X Marijuana Life S.. 0.00 % 0.86 %

N/A

CAD 0.06B
MUSC:CA Manulife Multifactor U.S... 0.00 % 0.62 %

N/A

CAD 3.66M
NIFE 0.00 % 0.00 %

N/A

N/A
CBDX:LSE 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
CBSX:XETRA 0.00 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
BLUM:F 0.00 % 0.00 %

N/A

N/A
CBSX:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.54% 55% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.54% 55% F 37% F
Trailing 12 Months  
Capital Gain -0.28% 65% D 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.28% 65% D 43% F
Trailing 5 Years  
Capital Gain -15.96% 70% C- 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.96% 70% C- 36% F
Average Annual (5 Year Horizon)  
Capital Gain -0.19% 48% F 38% F
Dividend Return -0.19% 48% F 33% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.84% 94% A 71% C-
Risk Adjusted Return -0.79% 47% F 33% F
Market Capitalization 7.29B 97% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.